Moleculera

Rethinking The Treatment Of Psychiatric Disorders

About this Event

Moleculera Biosciences is a precision medicine company focused on uncovering the immune-mediated roots of and guiding the treatment of a wide range of chronic and debilitating disorders.

Immune dysfunction and inflammation have been known to be the root cause of some of the most difficult to diagnose and most devastating diseases. In fact, up to 85% of psychiatric disorders, including ADHD, OCD, Schizophrenia, and Autism, are now known to have immune-mediated causes. That’s why many patients don’t respond to traditional psychotropic medications and treatments.

In response, Moleculera created their Autoimmune Brain Panel which identifies antibodies leading to neuropsychiatric disorders. Clinically validated in more than 15,000 patients, the impact of Moleculera’s breakthrough has been both wide-ranging and immediate.

Moleculera has also built the world’s largest biorepository and bioinformatics database of clinically annotated specimens from patients suffering from immune-mediated disorders. This fuels the discovery and development of novel biomarkers and potential therapeutic targets. Using their exclusive data, the company has several additional testing panels in the pipeline targeting cardiovascular, Long-COVID, and neurodegenerative disorders.

Register now to watch our fireside chat with:
  • Craig Shimasaki, PhD: President & CEO, Moleculera Biosciences. Craig is a scientist, businessperson, and serial entrepreneur whose work spans all stages of research and development from bench to bedside. He co-founded several companies, led multiple products through the FDA approval process and is a co-inventor on several patents.
  • Rodney Cotton: Rod built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company

Video On Demand

– Recorded

November 4

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.